A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in
postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor
receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.